EOLS (Evolus) Tariff Resilience Score: 3/10 (As of Jul. 04, 2026)


EOLS Evolus Inc EOLS
66 GF Score
Price $6.90
GF Value $13.63
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Evolus Tariff Resilience Score?

Evolus EOLS +2.22% 66 Tariff Resilience Score is 3 as of Jul. 04, 2026. GuruFocus rates EOLS with a GF Score™ of 66/100 and a GF Value™ of $13.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Evolus ranks better than 77.48% on this metric.

Evolus has the Tariff Resilience Score of 3, which implies that the company might have .

Evolus has Evolus is highly vulnerable to tariffs due to its reliance on imported products for its aesthetic treatments. The company has faced significant impacts from past tariff changes and has limited pricing power. While exploring alternative suppliers, it remains exposed to international trade policies.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Evolus might have .

Evolus  (NAS:EOLS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Evolus Tariff Resilience Score Related Terms

EOLS vs NIKA, EBS, ELTP: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolus Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Evolus's Tariff Resilience Score falls into.


EOLS
66GF Score
Evolus Inc EOLS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 3 mean?
Evolus (EOLS) has a Tariff Resilience Score of 3 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Evolus ranks #232 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 22.5%.
Is Evolus' Tariff Resilience Score too high?
Evolus' current Tariff Resilience Score is 3. Based on the distribution chart, Evolus ranks #232 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evolus has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Tariff Resilience Score compare to NIKA and EBS?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #232 out of 1030 companies for Tariff Resilience Score. This places Evolus in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Evolus's current Tariff Resilience Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.63, compared to a current price of $6.90 — trading 49.4% below its estimated fair value. The current Tariff Resilience Score is 3. Evolus' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Evolus (EOLS), the current Tariff Resilience Score is 3 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (EOLS) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of $6.90 is trading 49.4% below its estimated GF Value™ of $13.63. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for EOLS:

  • Tariff Resilience Score: 3
  • GF Value™: $13.63 vs. price of $6.90 (49.4% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolus Business Description

Other Exchanges EVL:Germany
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
66GF Score

Get the complete analysis for EOLS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.90
Price
$13.63
GF Value